INSC
gene geneOn this page
Summary
INSC (INSC spindle orientation adaptor protein, HGNC:33116) is a protein-coding gene on chromosome 11p15.2, encoding Protein inscuteable homolog (Q1MX18). May function as an adapter linking the Par3 complex to the GPSM1/GPSM2 complex.
In Drosophila, neuroblasts divide asymmetrically into another neuroblast at the apical side and a smaller ganglion mother cell on the basal side. Cell polarization is precisely regulated by 2 apically localized multiprotein signaling complexes that are tethered by Inscuteable, which regulates their apical localization (Izaki et al., 2006 [PubMed 16458856]).
Source: NCBI Gene 387755 — RefSeq curated summary.
At a glance
- GWAS associations: 9
- Clinical variants (ClinVar): 121 total
- MANE Select transcript:
NM_001042536
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:33116 |
| Approved symbol | INSC |
| Name | INSC spindle orientation adaptor protein |
| Location | 11p15.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000188487 |
| Ensembl biotype | protein_coding |
| OMIM | 610668 |
| Entrez | 387755 |
Gene structure
Transcript identifiers
Ensembl transcripts: 14 — 12 protein_coding, 2 protein_coding_CDS_not_defined
ENST00000379554, ENST00000379556, ENST00000424273, ENST00000447214, ENST00000525218, ENST00000526102, ENST00000528567, ENST00000530161, ENST00000876188, ENST00000876189, ENST00000876190, ENST00000876191, ENST00000961585, ENST00000961586
RefSeq mRNA: 6 — MANE Select: NM_001042536
NM_001031853, NM_001042536, NM_001278313, NM_001278314, NM_001278315, NM_001278316
CCDS: CCDS41621, CCDS41622, CCDS60735, CCDS60736
Canonical transcript exons
ENST00000379556 — 13 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001379365 | 15177111 | 15177163 |
| ENSE00001383198 | 15178324 | 15178447 |
| ENSE00001538075 | 15114923 | 15115003 |
| ENSE00001599511 | 15175741 | 15176086 |
| ENSE00002184057 | 15245912 | 15247208 |
| ENSE00002687078 | 15200824 | 15200949 |
| ENSE00003458444 | 15238919 | 15239074 |
| ENSE00003495607 | 15235602 | 15235668 |
| ENSE00003497422 | 15190701 | 15190814 |
| ENSE00003509945 | 15240447 | 15240523 |
| ENSE00003529591 | 15221477 | 15221648 |
| ENSE00003581028 | 15225650 | 15225828 |
| ENSE00003649808 | 15149130 | 15149230 |
Expression profiles
Bgee: expression breadth ubiquitous, 158 present calls, max score 89.71.
FANTOM5 (CAGE): breadth broad, TPM avg 1.9315 / max 151.2291, expressed in 240 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 113231 | 1.6337 | 224 |
| 113232 | 0.2265 | 84 |
| 206198 | 0.0713 | 2 |
Top tissues by expression
249 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| tibia | UBERON:0000979 | 89.71 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 86.77 | gold quality |
| secondary oocyte | CL:0000655 | 86.51 | gold quality |
| dorsal root ganglion | UBERON:0000044 | 85.10 | gold quality |
| oocyte | CL:0000023 | 85.08 | gold quality |
| tibial nerve | UBERON:0001323 | 83.40 | gold quality |
| trigeminal ganglion | UBERON:0001675 | 83.23 | gold quality |
| sural nerve | UBERON:0015488 | 80.26 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 76.64 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 76.11 | gold quality |
| buccal mucosa cell | CL:0002336 | 76.07 | gold quality |
| cartilage tissue | UBERON:0002418 | 73.67 | silver quality |
| transverse colon | UBERON:0001157 | 72.21 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 71.85 | silver quality |
| colon | UBERON:0001155 | 71.52 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 71.26 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 71.05 | gold quality |
| lower esophagus | UBERON:0013473 | 70.98 | gold quality |
| large intestine | UBERON:0000059 | 70.52 | gold quality |
| intestine | UBERON:0000160 | 70.22 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 70.10 | gold quality |
| small intestine | UBERON:0002108 | 69.95 | gold quality |
| rectum | UBERON:0001052 | 68.92 | gold quality |
| body of stomach | UBERON:0001161 | 66.07 | gold quality |
| right atrium auricular region | UBERON:0006631 | 65.16 | gold quality |
| popliteal artery | UBERON:0002250 | 64.82 | gold quality |
| tibial artery | UBERON:0007610 | 64.77 | gold quality |
| stomach | UBERON:0000945 | 64.32 | gold quality |
| cardiac atrium | UBERON:0002081 | 64.18 | gold quality |
| vermiform appendix | UBERON:0001154 | 63.88 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 3.57 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
49 targeting INSC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-656-3P | 100.00 | 72.15 | 2788 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-7110-3P | 100.00 | 73.18 | 2486 |
| HSA-MIR-4455 | 100.00 | 65.48 | 1587 |
| HSA-MIR-4481 | 100.00 | 66.42 | 1669 |
| HSA-MIR-3689D | 100.00 | 66.14 | 1181 |
| HSA-MIR-6851-5P | 100.00 | 65.63 | 1294 |
| HSA-MIR-568 | 99.98 | 69.86 | 2084 |
| HSA-MIR-4789-5P | 99.98 | 70.76 | 2721 |
| HSA-MIR-3658 | 99.96 | 73.87 | 4379 |
| HSA-MIR-570-3P | 99.96 | 72.41 | 4910 |
| HSA-MIR-4666A-3P | 99.96 | 71.71 | 3434 |
| HSA-MIR-4487 | 99.96 | 64.58 | 1252 |
| HSA-MIR-6772-5P | 99.94 | 67.01 | 577 |
| HSA-MIR-1305 | 99.91 | 71.43 | 3443 |
| HSA-MIR-1297 | 99.91 | 73.41 | 3162 |
| HSA-MIR-5680 | 99.91 | 69.83 | 3421 |
| HSA-MIR-6124 | 99.87 | 69.78 | 3551 |
| HSA-MIR-5003-3P | 99.85 | 69.29 | 2517 |
| HSA-MIR-4760-5P | 99.80 | 69.88 | 1619 |
| HSA-MIR-498-5P | 99.76 | 69.64 | 1807 |
| HSA-MIR-494-3P | 99.70 | 71.45 | 2795 |
| HSA-MIR-33A-3P | 99.70 | 70.27 | 3362 |
| HSA-MIR-4729 | 99.69 | 72.18 | 4233 |
| HSA-MIR-561-3P | 99.64 | 70.90 | 3647 |
| HSA-MIR-8061 | 99.63 | 69.44 | 1411 |
| HSA-MIR-6716-5P | 99.56 | 68.62 | 1244 |
| HSA-MIR-510-3P | 99.54 | 70.06 | 2965 |
| HSA-MIR-4519 | 99.48 | 66.10 | 859 |
| HSA-MIR-6083 | 99.47 | 68.73 | 2393 |
Literature-anchored findings (GeneRIF, showing 7)
- cloning of two distinct cDNAs from Insc gene, which is differentially expressed from alternative first exons;Insc proteins bind to the Pins homologues LGN and AGS3, and also to Par3 and Par3beta (PMID:16458856)
- These data present AGS3, G-proteins, and mInsc as candidate proteins involved in regulating cellular stress associated with protein-processing pathologies. (PMID:20065032)
- mInsc-LGN interaction is vital for stabilization of LGN and for intracellular localization of mInsc. (PMID:22074847)
- Studies indicate that the Inscuteable (Insc)and NuMA are mutually exclusive interactors of LGN. (PMID:22977735)
- In mammary stem cells, the asymmetric domain of Insc bound to LGN:Galphai(GDP) suffices to drive asymmetric fate, and reverts aberrant symmetric divisions induced by p53 loss. (PMID:29523789)
- Genome-wide association study identified INSC gene associated with Trail Making Test Part A and Alzheimer’s disease related cognitive phenotypes. (PMID:34224794)
- A missense mutation in human INSC causes peripheral neuropathy. (PMID:38589651)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Insc | ENSMUSG00000048782 |
| rattus_norvegicus | Insc | ENSRNOG00000024712 |
| drosophila_melanogaster | insc | FBGN0011674 |
| caenorhabditis_elegans | WBGENE00018392 |
Protein
Protein identifiers
Protein inscuteable homolog — Q1MX18 (reviewed: Q1MX18)
All UniProt accessions (2): A0A0A0MSI1, Q1MX18
UniProt curated annotations — full annotation on UniProt →
Function. May function as an adapter linking the Par3 complex to the GPSM1/GPSM2 complex. Involved in spindle orientation during mitosis. May regulate cell proliferation and differentiation in the developing nervous system. May play a role in the asymmetric division of fibroblasts and participate in the process of stratification of the squamous epithelium.
Subunit / interactions. Interacts with ALS2CR19/PAR3B and F2RL2/PAR3. Interacts with GPSM1/AGS3 and GPSM2/LGN (via TPR repeat region). Identified in a complex with GPSM2 and F2RL2.
Subcellular location. Cytoplasm. Cell cortex.
Tissue specificity. Isoform 1 is expressed in various tissues with stronger expression in liver, kidney and small intestine. Isoform 2 is abundantly expressed in small intestine and to a lower extent in lung and pancreas.
Isoforms (6)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q1MX18-1 | 1, Long | yes |
| Q1MX18-2 | 2, Short | |
| Q1MX18-3 | 3 | |
| Q1MX18-4 | 4 | |
| Q1MX18-5 | 5 | |
| Q1MX18-6 | 6 |
RefSeq proteins (6): NP_001027024, NP_001036001, NP_001265242, NP_001265243, NP_001265244, NP_001265245 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000225 | Armadillo | Repeat |
| IPR011989 | ARM-like | Homologous_superfamily |
| IPR016024 | ARM-type_fold | Homologous_superfamily |
| IPR031938 | INSC_LBD | Domain |
| IPR038205 | INSC_LBD_sf | Homologous_superfamily |
| IPR039921 | Inscuteable | Family |
| IPR045789 | Insc_C | Domain |
Pfam: PF16748, PF19427
UniProt features (24 total): sequence conflict 6, splice variant 6, mutagenesis site 3, sequence variant 2, helix 2, strand 2, chain 1, region of interest 1, short sequence motif 1
Structure
Experimental structures (PDB)
1 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 3SF4 | X-RAY DIFFRACTION | 2.6 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q1MX18-F1 | 83.44 | 0.70 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Mutagenesis-validated functional residues (3):
| Position | Phenotype |
|---|---|
| 78 | abolishes interaction with gpsm2. |
| 89 | strongly reduces interaction with gpsm2. abolishes interaction with gpsm2 and gpsm1; when associated with d-97. |
| 97 | abolishes interaction with gpsm2 and gpsm1; when associated with r-89. |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 51 (showing top):
GOBP_APICAL_PROTEIN_LOCALIZATION, GOBP_ASYMMETRIC_CELL_DIVISION, GOBP_REGULATION_OF_CELL_DIVISION, GOBP_REGULATION_OF_PROTEIN_STABILITY, GOCC_CYTOPLASMIC_REGION, GOCC_APICAL_PART_OF_CELL, GOCC_CELL_CORTEX_REGION, GOBP_CELL_DIVISION, GOMF_CYTOSKELETAL_ANCHOR_ACTIVITY, BOCHKIS_FOXA2_TARGETS, OHGUCHI_LIVER_HNF4A_TARGETS_DN, GOCC_APICAL_CORTEX, GSE13522_CTRL_VS_T_CRUZI_BRAZIL_STRAIN_INF_SKIN_DN, PAX3_TARGET_GENES, MIR3658
GO Biological Process (6): nervous system development (GO:0007399), asymmetric cell division (GO:0008356), regulation of asymmetric cell division (GO:0009786), cell differentiation (GO:0030154), regulation of protein stability (GO:0031647), apical protein localization (GO:0045176)
GO Molecular Function (4): cytoskeletal adaptor activity (GO:0008093), protein domain specific binding (GO:0019904), protein-macromolecule adaptor activity (GO:0030674), protein binding (GO:0005515)
GO Cellular Component (5): plasma membrane (GO:0005886), protein-containing complex (GO:0032991), apical cortex (GO:0045179), cytoplasm (GO:0005737), cell cortex (GO:0005938)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| protein binding | 2 |
| cell periphery | 2 |
| system development | 1 |
| cell division | 1 |
| asymmetric cell division | 1 |
| regulation of cell division | 1 |
| cellular developmental process | 1 |
| regulation of biological quality | 1 |
| intracellular protein localization | 1 |
| cytoskeletal protein binding | 1 |
| protein-macromolecule adaptor activity | 1 |
| molecular adaptor activity | 1 |
| binding | 1 |
| membrane | 1 |
| cellular_component | 1 |
| cell cortex region | 1 |
| intracellular anatomical structure | 1 |
| cellular anatomical structure | 1 |
| cytoplasm | 1 |
Protein interactions and networks
STRING
790 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| INSC | GPSM2 | P81274 | 853 |
| INSC | PARD3B | Q8TEW8 | 831 |
| INSC | PARD3 | Q8TEW0 | 620 |
| INSC | LGALS4 | P56470 | 598 |
| INSC | GPSM1 | Q86YR5 | 583 |
| INSC | NUMA1 | Q14980 | 518 |
| INSC | TH | P07101 | 471 |
| INSC | NUMBL | Q9Y6R0 | 450 |
| INSC | NUMB | P49757 | 447 |
| INSC | NES | P48681 | 435 |
| INSC | POU3F4 | P49335 | 434 |
| INSC | PAX6 | P26367 | 426 |
| INSC | SOX2 | P48431 | 417 |
| INSC | PRR12 | Q9ULL5 | 412 |
| INSC | SCAF1 | Q9H7N4 | 382 |
IntAct
43 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| GPSM2 | INSC | psi-mi:“MI:0915”(physical association) | 0.670 |
| INSC | TTC23 | psi-mi:“MI:0915”(physical association) | 0.560 |
| INSC | USP54 | psi-mi:“MI:0915”(physical association) | 0.560 |
| INSC | LHX3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SORBS3 | INSC | psi-mi:“MI:0915”(physical association) | 0.560 |
| INSC | RUSC1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| INSC | MGC50722 | psi-mi:“MI:0915”(physical association) | 0.560 |
| INSC | TEKT3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GEM | INSC | psi-mi:“MI:0915”(physical association) | 0.560 |
| PRR35 | INSC | psi-mi:“MI:0915”(physical association) | 0.560 |
| GPANK1 | INSC | psi-mi:“MI:0915”(physical association) | 0.560 |
| INSC | ZNF587 | psi-mi:“MI:0915”(physical association) | 0.560 |
| INSC | SMARCD1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| INSC | A2ML1 | psi-mi:“MI:0914”(association) | 0.350 |
| INSC | GPSM2 | psi-mi:“MI:0915”(physical association) | 0.000 |
| INSC | USP54 | psi-mi:“MI:0915”(physical association) | 0.000 |
| INSC | SORBS3 | psi-mi:“MI:0915”(physical association) | 0.000 |
| INSC | LHX3 | psi-mi:“MI:0915”(physical association) | 0.000 |
| INSC | RUSC1 | psi-mi:“MI:0915”(physical association) | 0.000 |
| MGC50722 | INSC | psi-mi:“MI:0915”(physical association) | 0.000 |
| TEKT3 | INSC | psi-mi:“MI:0915”(physical association) | 0.000 |
| GEM | INSC | psi-mi:“MI:0915”(physical association) | 0.000 |
| PRR35 | INSC | psi-mi:“MI:0915”(physical association) | 0.000 |
| GPANK1 | INSC | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (29): INSC (Two-hybrid), INSC (Two-hybrid), INSC (Two-hybrid), INSC (Two-hybrid), INSC (Two-hybrid), INSC (Two-hybrid), INSC (Two-hybrid), INSC (Two-hybrid), INSC (Two-hybrid), INSC (Two-hybrid), ZNF587 (Two-hybrid), GPANK1 (Two-hybrid), MGC50722 (Two-hybrid), GPSM2 (Affinity Capture-MS), DNAJC1 (Affinity Capture-MS)
ESM2 similar proteins: A0A8M9QN10, A0JM49, A0JP94, A1EC95, A2AKG8, A2BID5, A9JRI0, B2RYI0, C5J7W8, E7FAW3, E7FGT5, E7FH61, O60287, P42695, P42858, P42859, P49815, P49816, P51111, P51112, Q1MX18, Q3HNM7, Q3U829, Q3UGY8, Q3UHQ6, Q3URQ0, Q571H0, Q5JWR5, Q5R5R2, Q5R6T6, Q5RDK1, Q5TH69, Q5VW36, Q5ZM41, Q61037, Q640K1, Q642P2, Q6A009, Q6AI08, Q6GN08
Diamond homologs: Q1MX18, Q3HNM7
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
121 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 103 |
| Likely benign | 6 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2795 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 11:15112578:G:T | donor_gain | 1.0000 |
| 11:15138711:TCA:T | donor_gain | 1.0000 |
| 11:15149228:GCG:G | donor_gain | 1.0000 |
| 11:15175732:T:A | acceptor_gain | 1.0000 |
| 11:15175736:TGCA:T | acceptor_loss | 1.0000 |
| 11:15175737:GCA:G | acceptor_loss | 1.0000 |
| 11:15175738:CAGG:C | acceptor_loss | 1.0000 |
| 11:15175739:A:AG | acceptor_gain | 1.0000 |
| 11:15175739:AGGC:A | acceptor_loss | 1.0000 |
| 11:15175740:G:GG | acceptor_gain | 1.0000 |
| 11:15176062:G:GT | donor_gain | 1.0000 |
| 11:15176075:G:GT | donor_gain | 1.0000 |
| 11:15176076:A:T | donor_gain | 1.0000 |
| 11:15178439:G:T | donor_gain | 1.0000 |
| 11:15178443:TTCAG:T | donor_loss | 1.0000 |
| 11:15178444:TCAG:T | donor_loss | 1.0000 |
| 11:15178445:CAGGT:C | donor_loss | 1.0000 |
| 11:15178446:AGG:A | donor_loss | 1.0000 |
| 11:15178447:GGTC:G | donor_loss | 1.0000 |
| 11:15178448:G:C | donor_loss | 1.0000 |
| 11:15178449:T:G | donor_loss | 1.0000 |
| 11:15190695:TCTTA:T | acceptor_loss | 1.0000 |
| 11:15190696:CTTAG:C | acceptor_loss | 1.0000 |
| 11:15190697:TTAGG:T | acceptor_loss | 1.0000 |
| 11:15190698:TAGGC:T | acceptor_loss | 1.0000 |
| 11:15190699:A:AG | acceptor_gain | 1.0000 |
| 11:15190699:A:C | acceptor_loss | 1.0000 |
| 11:15190700:G:A | acceptor_loss | 1.0000 |
| 11:15190700:G:GG | acceptor_gain | 1.0000 |
| 11:15190813:AGGTG:A | donor_loss | 1.0000 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000045599 (11:15130822 A>G), RS1000072156 (11:15143136 A>G), RS1000091999 (11:15135997 C>G), RS1000118304 (11:15142975 A>G), RS1000118770 (11:15222736 A>G), RS1000119498 (11:15226869 A>G,T), RS1000136727 (11:15184149 A>G), RS1000140235 (11:15144917 A>C,G), RS1000157472 (11:15229006 T>C), RS1000188863 (11:15149186 G>A), RS1000193970 (11:15217649 T>G), RS1000194088 (11:15136472 G>A,T), RS1000207381 (11:15182801 T>G), RS1000209815 (11:15178600 GTGA>G), RS1000222003 (11:15269103 T>C)
Disease associations
OMIM: gene MIM:610668 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
9 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST001762_863 | Obesity-related traits | 6.000000e-06 |
| GCST002013_6 | Menarche (age at onset) | 9.000000e-06 |
| GCST002611_2 | Expressive vocabulary in infants | 2.000000e-07 |
| GCST006288_115 | Heel bone mineral density | 7.000000e-07 |
| GCST006288_29 | Heel bone mineral density | 1.000000e-15 |
| GCST006288_726 | Heel bone mineral density | 3.000000e-09 |
| GCST006979_620 | Heel bone mineral density | 8.000000e-59 |
| GCST006979_621 | Heel bone mineral density | 1.000000e-16 |
| GCST006979_622 | Heel bone mineral density | 1.000000e-19 |
EFO canonical traits (4, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0003939 | energy intake |
| EFO:0004703 | age at menarche |
| EFO:0006316 | infant expressive language ability |
| EFO:0009270 | heel bone mineral density |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
25 total (human), top 25 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects cotreatment, increases expression, decreases methylation | 5 |
| trichostatin A | affects cotreatment, increases expression | 3 |
| Vorinostat | affects cotreatment, increases expression | 2 |
| Panobinostat | affects cotreatment, increases expression | 2 |
| Benzo(a)pyrene | decreases methylation, increases expression, increases methylation | 2 |
| 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt | affects cotreatment, increases expression | 1 |
| bisphenol A | affects cotreatment, decreases methylation | 1 |
| sodium arsenite | increases expression | 1 |
| cupric chloride | increases expression | 1 |
| perfluorooctane sulfonic acid | increases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, increases expression | 1 |
| abrine | increases expression | 1 |
| dorsomorphin | affects cotreatment, increases expression | 1 |
| Fulvestrant | affects cotreatment, decreases methylation, increases methylation | 1 |
| Arsenic | affects methylation | 1 |
| Chenodeoxycholic Acid | affects cotreatment, increases expression | 1 |
| Deoxycholic Acid | affects cotreatment, increases expression | 1 |
| Glycochenodeoxycholic Acid | affects cotreatment, increases expression | 1 |
| Glycocholic Acid | affects cotreatment, increases expression | 1 |
| Glycodeoxycholic Acid | affects cotreatment, increases expression | 1 |
| Thiram | increases expression | 1 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | affects expression | 1 |
| Cyclosporine | increases expression | 1 |
| Tungsten Compounds | decreases expression | 1 |
| Okadaic Acid | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.